Company newsForm 8-K and release

SELLAS Life Sciences Group SLS

SELLAS Life Sciences Group prices 11,538,462-share offering at $13.00 per share

The company said it expects gross proceeds of $150.0 million before underwriting discounts and commissions and offering expenses.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On November 18, 2026, SELLAS Life Sciences Group entered into an underwriting agreement with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the underwriters, for a public offering of 11,538,462 shares of its common stock, par value $0.0001 per share. All of the shares are being sold by the company at $13.00 per share.

The underwriters also received a 30-day option to buy up to 1,730,769 additional shares of common stock on the same terms. The company said it expects net proceeds of approximately $161.8 million, including proceeds from the underwriters' full exercise of the option, after underwriting discounts and commissions and estimated offering expenses.

The offering is being made under the company's shelf registration statement on Form S-3, which was automatically effective upon filing. A final prospectus supplement supplements that registration statement.

The underwriting agreement includes customary representations, warranties, closing conditions and termination provisions. It also provides for indemnification between the company and the underwriters, including for liabilities under the Securities Act of 1933, as amended.

Key facts

Price per share
$13.00
Shares offered
11,538,462 shares of common stock
Underwriter option
Up to 1,730,769 additional shares for 30 days
Expected gross proceeds
$150.0 million before underwriting discounts and offering expenses
Expected net proceeds
Approximately $161.8 million, including full exercise of the option

All SLS news

Sources: Form 8-K filed November 20, 2026, and the company's release on GlobeNewswire, November 17, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

SELLAS Life Sciences Group first, then the newest

All company news